Relapse prevention in schizophrenia: Attitudes of neurologists-psychiatrists

European Psychiatry

Volumn 16, Issue 2, 2001, Pages 90-98

  Bergiannaki, J D ^a   Hatzimanolis, J ^a   Liappas, J ^a   Sakkas, P N ^a   Stefanis, C N ^a  

^a UNIVERSITY MENTAL HEALTH RESEARCH INSTITUTE   (Greece)

Author keywords

Neurologists psychiatrists; Prevention; Relapse; Schizophrenia; Treatment attitudes

Indexed keywords

HALOPERIDOL;

ADULT; ARTICLE; CONTINUING EDUCATION; DRUG INDUCED DISEASE; EXPERIENCE; FEMALE; GREECE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PREVENTION; PRIORITY JOURNAL; PSYCHIATRIST; QUESTIONNAIRE; RECURRENCE RISK; RELAPSE; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ADULT; ANTIPSYCHOTIC AGENTS; ATTITUDE OF HEALTH PERSONNEL; FEMALE; GREECE; HALOPERIDOL; HUMANS; MALE; MENTAL HEALTH SERVICES; NEUROLOGY; PATIENT COMPLIANCE; PATIENT EDUCATION; PHYSICIAN'S PRACTICE PATTERNS; PSYCHIATRY; QUESTIONNAIRES; RECURRENCE; SCHIZOPHRENIA; TIME FACTORS;

EID: 0035078501     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-9338(01)00543-0     Document Type: Article

References (57)

1. Effects on assassination attempts on Lafontaine and Schauble on public opinion about psychiatric patients. Part 2: 1991 development
2. Significance of neuroleptic dose and plasma levels in the pharmacological treatment of psychoses
3. Informationszentrierte Angehörigengruppen zur Complianceverbesserung bei schizophrenen Patienten
4. New antipsychotic medications: What advantages do they offer?
5. The Northwick Park study of first episodes of schizophrenia: II. A randomized controlled trial of prophylactic neuroleptic treatment
6. Overview: Maintenance of therapy in psychiatry
7. Antipsychotic drugs
8. Maintenance medication
9. Determinants of medication compliance in schizophrenia: Empirical and clinical findings
10. The current status of maintenance treatment in schizophrenia
11. Towards the improvement of compliance: The significance of psycho-education and new antipsychotic drugs
12. Indikation zur neuroleptischen Langzeitmedikation - Standardverfahren oder individualprognostisch geleitete Intervention?
13. One-year outcome of schizophrenic patients - The interaction of chronicity and neuroleptic treatment
14. Conclusions and treatment recommendations for the acute episode in schizophrenia
15. Tardive dyskinesia
16. Concluding remarks
17. Die Behandlungskontinuität bei schizophrenen patienten in der ambulanz. Eine Fünfjahresnachuntersuchung
18. Compliance - Ein Komplexes Problem
19. The cost of schizophrenia
20. Estimating the economic costs of schizophrenia
21. Collaborative Study Group. Drug and sociotherapy in the aftercare of schizophrenic patients: One year relapse rates
22. Resistance of schizophrenic patients to social and vocational rehabilitation
23. Psycho-educational training for schizophrenic patients: Background, procedure and empirical findings
24. Antipsychotic dosing strategies in acute schizophrenia
25. The Northwick Park study of first episodes of schizophrenia. I. Presentation of the illness and problems relating to admission
26. How high is the relapse rate in schizophrenia?
27. Problems of compliance in the outpatient treatment of schizophrenia
28. Compliance issues in outpatient treatment
29. Treatment of schizophrenia
30. Dosage and route of administration of neuroleptic drugs during different phases of a schizophrenic illness
31. Fluphenazine versus placebo in patients with remitted acute first episode schizophrenia
32. Integrating incidence and prevalence of tardive dyskinesia
33. Depot neuroleptics - A step forward? Consensus regarding indication for prophylactic neuroleptic treatment -necessary, but unattainable?
34. Compliance, quality assurance and standards for relapse prevention in schizophrenia
35. Guidelines for neuroleptic relapse prevention in schizophrenia: Towards a consensus view
36. Survey Co-Investigators of the PORT Project. Patterns of usual care for schizophrenia: Initial results from the schizophrenia patient outcomes research team (PORT) client survey
37. Therapeutische Gruppenarbeit mit Angehörigen schizophrener Patienten
38. A scale for detection of negative attitude towards medication among relatives of schizophrenic patients
39. Is tardive dyskinesia a unique disorder?
40. The role of dosage and plasma levels in neuroleptic relapse prevention
41. Pharmacological treatment strategies in acute schizophrenia
42. Klinikaufenthalte und produktive Rückfalle bei ersterkrankten Schizophrenen
43. Optimal dose of neuroleptics in acute schizophrenia: A controlled study of the neuroleptic threshold and higher haloperidol dose
44. A selective review of recent North America long-term follow-up studies of schizophrenia
45. Perspectives on treatment needs in schizophrenia
46. Outcome study of first episode psychosis: I. Relapse rates after one year
47. The economic burden of mental illness
48. A historical review of the adverse reactions to neuroleptic agents
49. The evaluation and treatment of first-episode psychosis
50. The natural history of schizophrenia: A five-year follow-up study of outcome and prediction in a representative sample of schizophrenia
51. Maintenance neuroleptic treatment in schizophrenia
52. Why do schizophrenic patients refuse to take their drugs?